Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV autologous bone marrow-derived mesenchymal stem cells for chronic spinal cord injury (STR01-04)
jRCT1090220329Phase 2Recruiting
- Sponsor
- Toshihiko Yamashita, MD, PhD
- Start
- Feb 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in spinal cord injury (SCI), sponsored by Toshihiko Yamashita, MD, PhD. Primary endpoint: AIS improvement at 180 days. Started Feb 2018; status: recruiting.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on jRCT1090220329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220329.